CN101049442A - Preparation of Chinese traditional medicine of clearing away heat and promoting diuresis, promoting blood circulation and activating the channels, and preparation method - Google Patents
Preparation of Chinese traditional medicine of clearing away heat and promoting diuresis, promoting blood circulation and activating the channels, and preparation method Download PDFInfo
- Publication number
- CN101049442A CN101049442A CN 200610066921 CN200610066921A CN101049442A CN 101049442 A CN101049442 A CN 101049442A CN 200610066921 CN200610066921 CN 200610066921 CN 200610066921 A CN200610066921 A CN 200610066921A CN 101049442 A CN101049442 A CN 101049442A
- Authority
- CN
- China
- Prior art keywords
- preparation
- blood circulation
- damp
- clearing away
- away heat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000001737 promoting effect Effects 0.000 title claims abstract description 41
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 208000004880 Polyuria Diseases 0.000 title claims abstract description 25
- 230000035619 diuresis Effects 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims description 41
- 230000017531 blood circulation Effects 0.000 title claims description 20
- 230000003213 activating effect Effects 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 7
- 230000008569 process Effects 0.000 claims abstract description 5
- 239000000463 material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 238000001035 drying Methods 0.000 claims description 25
- 238000000576 coating method Methods 0.000 claims description 22
- 239000000706 filtrate Substances 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000011248 coating agent Substances 0.000 claims description 19
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 17
- 229920000881 Modified starch Polymers 0.000 claims description 17
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 17
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 17
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 17
- 239000002671 adjuvant Substances 0.000 claims description 15
- 239000012567 medical material Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 11
- 235000019634 flavors Nutrition 0.000 claims description 11
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 238000004064 recycling Methods 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007921 spray Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 241000545442 Radix Species 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- 241001676635 Lepidorhombus whiffiagonis Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 241001529739 Prunella <angiosperm> Species 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- -1 mixing Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 9
- 244000126155 Lycopus uniflorus Species 0.000 abstract 1
- 235000002280 Lycopus uniflorus Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 201000004595 synovitis Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 239000000945 filler Substances 0.000 description 9
- 239000009636 Huang Qi Substances 0.000 description 8
- 210000000629 knee joint Anatomy 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 241000521257 Hydrops Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N ferric oxide Chemical compound O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000000554 physical therapy Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229960003371 protocatechualdehyde Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 201000001819 hydrarthrosis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Abstract
A Chinese medicine in the form of tablet for treating clearing heat, promoting diuresis and activating blood to unblock collaterals is prepared from 4 Chinese- medicinal materials including prunella spike, tetrandra root, bugleweed, etc. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of clearing away heat-damp and promoting diuresis that has, Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral and preparation method thereof belongs to technical field of Chinese medicine.
Technical background
Gonarthritis, synovitis are a kind of multiple diseases, and its site of pathological change causes the temporary transient or long-term part disability of patient easily mainly in knee joint, and is all bigger to patient, social harm.At present, though, still have many patients not cure by many effective Therapeutic Method; In case miss the optimal treatment phase, inflammation gradates and is chronic phase, and hydrops shows effect repeatedly, and synovial membrane plumpness, adhesion have influence on the function problem in joint.Especially the young and middle-aged patient of part will bear many societies and home duties, the torment that is bearing the pain for a long time again simultaneously.Medical research is confirmed: gonarthromeningitis, and bursitis, traumatic arthritis, rheumatoid arthritis, rheumatic arthritis, hyperosteogeny diseases, the pain cause of generation are that the synovial membrane inflammation causes, so be summed up as the treatment synovitis at last.
Synovitis is to be the non-infectious inflammation of cardinal symptom with knee joint swelling, pain, hydrops, divides acute injury synovitis, chronic synovitis and degeneration synovitis.Treat at present synovitis clinically and adopt physical therapy means such as ultrashort wave, microwave to be equipped with the anti-inflammation and analgesic drugs of nonsteroidal more, and adopt hydrocortisone hormone medicine partial closure or intra-articular injection therapy.Physical therapy is better for the tangible patient's effect of acute stage swelling, but it is general for chronic synovitis curative effect, and it is long-term under physical therapy, the patient has leukopenia, the potential danger of immunity degradation, the hydrocortisone hormone medicine has powerful antiinflammatory, the effect of exudation has better therapeutic effect to the synovitis hydrarthrosis, but to articular cartilage, tendon and ligament all have infringement, continuous several times is used, cause easily and organize degeneration that the many benefits of fraud are few, therefore, physical therapy and hormone, non_steroidal anti_inflammatory drug, take out hydrops, the flushing articular cavity, though the treatment of antibiotics has certain curative effect, but drug side effect is more, treats not thoroughly, may rebound.Chinese medicine thinks that this disease belongs to the category of diseases such as " arthromyodynia ", " arthroncus of knee ".Along with the continuous development of Chinese medicine, reliable, the painful Chinese medicine little, few side effects of employing curative effect becomes research direction in recent years.
Theory of Chinese medical science is thought, synovitis belongs to the traditional Chinese medical science " arthromyodynia " category, its pathogenesis is " a damp and hot resistance network; retention of water-damp ", but sick wasting QI-blood for a long time and have deficient time concurrently, and wound can cause blood stasis again simultaneously, strongly fragrant and the heat-transformation of long-pending stasis of blood hydrops or damp, damp and hotly fight mutually, cause the knee joint heating and swell and ache, the heat muscles contracture of burning causes the joint and can not bend and stretch.The synovitis capsule is a pure Chinese medicinal preparation, it mainly is made up of medicines such as Spica Prunellae, Radix Stephaniae Tetrandrae, Herba Lycopi, Herba Siegesbeckiae, Fructus Ligustri Lucidi, Semen Coicis, Radix Salviae Miltiorrhizae, Folium Mahoniae, Rhizoma Smilacis Glabraes, based on clearing away heat-damp and promoting diuresis, assistant is with benefiting vital QI and blood, promoting blood circulation to remove obstruction in the collateral medicine, aspect the patient of the acute and chronic synovitis of treatment, knee joint postoperative significant curative effect is being arranged, be subjected to the welcome of hospitalized patients deeply, occupy suitable share in market.Right in the easy moisture absorption of original capsule is lumpd, the softgel shell embrittlement is easily gone mouldy simultaneously, and the inconvenience of swallowing, mouthfeel is poor, less stable, and clinical use is limited, in order to enrich the dosage form kind, better benefit the numerous common people, the inventor furthers investigate it, has developed the synovitis sheet, by retrieval, said preparation still belongs to internal blank.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical preparation that is used for the treatment of acute and chronic synovitis and knee joint postoperative patient and preparation method thereof.Said preparation mainly is made up of medicines such as Spica Prunellae, Radix Stephaniae Tetrandrae, Herba Lycopi, Herba Siegesbeckiae, Fructus Ligustri Lucidi, Semen Coicis, Radix Salviae Miltiorrhizae, Folium Mahoniae, Rhizoma Smilacis Glabraes, has clearing away heat-damp and promoting diuresis, the merit of promoting blood circulation to remove obstruction in the collateral.Clinical efficacy is remarkable, so the comparatively difficulty because original capsule is swallowed is easy to the moisture absorption, less stable, be subjected to certain limitation clinically, in order to enrich the dosage form kind, better bring into play the curative effect of this medicine, the applicant further studies it, developed the tablet of this medicine, not only kept the curative effect of former preparation preferably, and taken, carry, preserve more convenient, stability also greatly improves.
The present invention is achieved by the following technical solutions:
A kind of have a clearing away heat-damp and promoting diuresis, and the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral is characterized in that, counts by weight percentage, and it is mainly to be prepared from by active ingredient 90-70% and adjuvant 10-30%.Described active ingredient mainly is made up of following raw material medicaments in part by weight: 2 parts of Spica Prunellaes, 1.33 parts of Radixs Stephaniae Tetrandrae, Herba Lycopi's 0.6 1 part of Fen, Herba Siegesbeckiae, 1 part of Fructus Ligustri Lucidi, 2 parts of Semen Coiciss, 1 part of Radix Salviae Miltiorrhizae, 1 part of Folium Mahoniae, 1.33 parts of Rhizoma Smilacis Glabraes, 0.67 part of Radix Angelicae Sinensis, 1.33 parts of the Radixs Astragali, 1 part of Retinervus Luffae Fructus, 0.67 part of Radix Cyathulae.
Described preparation is meant tablet.
Described adjuvant includes but not limited to one or more of solvable or microsolubility calcium salt, starch, dextrin, lactose, pregelatinized Starch, microcrystalline Cellulose, mannitol, xylitol, micropowder silica gel, Pulvis Talci, magnesium stearate
Preferred adjuvant is meant microcrystalline Cellulose, pregelatinized Starch, magnesium stearate.
A kind of have a clearing away heat-damp and promoting diuresis, the preparation method of the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral: get 13 flavor medical materials such as Spica Prunellae, Radix Stephaniae Tetrandrae, decoct with water secondary, each 2 hours, collecting decoction filtered, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds ethanol, stirs evenly, leave standstill, filter filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), and drying is ground into fine powder, add adjuvant or do not add adjuvant, be prepared into required preparation with common process.
The preparation method of tablet is: get 13 flavor medical materials such as Spica Prunellae, Radix Stephaniae Tetrandrae, decoct with water secondary, add 6-10 times of water gaging at every turn, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), add the ethanol that 0.5-3 doubly measures, stir evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), drying, be ground into fine powder, add right amount of auxiliary materials, mixing is granulated, dry, tabletting, coating or coating not, promptly.
The tablet preferred manufacturing procedure is: get 13 flavor medical materials such as Spica Prunellae, Radix Stephaniae Tetrandrae, decoct with water secondary, add 8 times of water gagings at every turn, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds the ethanol of equivalent, stirs evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), dry, be ground into fine powder, add microcrystalline Cellulose and pregelatinized Starch (2: 1) in right amount, mixing, granulate, drying adds 1.0% magnesium stearate, tabletting, the bag film-coat, promptly.
The art for coating of tablet is: Opadry-Y-1-7000 is dissolved in 80% alcoholic solution, soaked 10 minutes, stir, ground 20 minutes through colloidal film, cross 200 mesh sieves and filter, remove coarse granule, with the blockage resisting spray gun, it is standby to make film liquid; Going fine powder to place the plain sheet sieve of suppressing is preheated in the coating pan about 45 ℃, start air compressor machine, open air cock, and the flow of regulating both makes carefully and uniformly vaporific, spray velocity do not cause powder to fly upward with control and in time drying be advisable, continue stirring at coating process film liquid; The coating parameter is: spray gun diameter: 1.4mm, nozzle and sheet bed spacing: 150mm, intake: 7m
2/ min, inlet temperature: 55 ℃, the gate temperature: preheating 5rpm/ changes, and coating: 12rpm/ changes, and drying: 5rpm/ changes, whiff pressure: 0.15mpa, hydrojet speed: 49g/min, drying: be placed on tray, placed the silica dehydrator chamber 3 hours; Promptly.
Theory of Chinese medical science is thought, synovitis belongs to the traditional Chinese medical science " arthromyodynia " category, its pathogenesis is " a damp and hot resistance network; retention of water-damp ", but sick wasting QI-blood for a long time and have deficient time concurrently, and wound can cause blood stasis again simultaneously, strongly fragrant and the heat-transformation of long-pending stasis of blood hydrops or damp, damp and hotly fight mutually, cause the knee joint heating and swell and ache, the heat muscles contracture of burning causes the joint and can not bend and stretch.We are based on clearing away heat-damp and promoting diuresis, and assistant is with benefiting vital QI and blood, promoting blood circulation to remove obstruction in the collateral medicine.Spica Prunellae has the effect of mass dissipating and swelling eliminating, liver heat removing and eyesight improving in the side, and Radix Stephaniae Tetrandrae, Rhizoma Smilacis Glabrae have the merit of inducing diuresis to remove edema, and Radix Angelicae Sinensis, Herba Lycopi have the effect of promoting blood circulation to remove obstruction in the collateral, more than is principal agent.Semen Coicis spleen invigorating eliminating dampness by diuresis is accessory drugs; But Radix Achyranthis Bidentatae is liver and kidney tonifying both, Gu its, but activating blood and eliminatng dampness is again controlled its mark, and giving consideration to both the incidental and fundamental is the monarch in the side; Herba Siegesbeckiae, Retinervus Luffae Fructus relaxing muscles and tendons and activating QI and blood in the collateral, removing dampness and detoxicating is for minister is helped to joining.Folium Mahoniae clearing away heat-damp and promoting diuresis, Radix Salviae Miltiorrhizae have the effect of dispelling phlegm and alleviating pain, promoting blood circulation to restore menstrual flow, and Fructus Ligustri Lucidi tool liver and kidney tonifying, YIN nourishing make eye bright, heart tonifying diuresis, hepatoprotective effect, effects such as Radix Astragali tool QI invigorating benefit is defended, toxin expelling granulation promoting, the Fructus Ligustri Lucidi nourishing YIN adds the Radix Astragali with QI invigorating, work in coordination, bring out the best in each other; Play clearing away heat-damp and promoting diuresis altogether, the merit of promoting blood circulation to remove obstruction in the collateral.Modern pharmacological research shows: the ursolic acid that generates after its effective ingredient prunellin hydrolysis of Spica Prunellae has diuresis, improves immunologic function and broad-spectrum antibacterial action; Contained alkaloid has analgesia, antiinflammatory, analgesic, diuresis in the Radix Stephaniae Tetrandrae; The volatile oil of Radix Angelicae Sinensis has antiinflammatory, removes effects such as oxygen-derived free radicals, hepatic cholagogic, protection kidney, raise immunity; Its effective ingredient Semen Coicis oil of Semen Coicis has calmness, alleviates the skeletal muscle spasm, and analgesic activity is arranged; Compositions such as berberine are arranged, the tool antiinflammatory action in the Folium Mahoniae; The effective ingredient of Fructus Ligustri Lucidi, Radix Salviae Miltiorrhizae has inhibitory action to staphylococcus aureus, and astragalus polysaccharides can obviously strengthen the human body immunity, improves human body anti allergic reaction ability, and the immune system of body is had regulating action; Herba Siegesbeckiae Han Herba Siegesbeckiae element brings high blood pressure down, effect such as calmness, rheumatism.Clinical trial shows that patient's total effective rates such as patient that this medicine of synovitis capsule/granule is treated acute and chronic synovitis and knee joint postoperative reach 91%, take continuously under therapeutic dose, side effect is rare, has higher safety.
At prior art, the easy moisture absorption and cause content tide knot in the original capsule storage process, the softgel shell embrittlement is broken, less stable; And exist volume bigger, the problems such as inconvenience of swallowing have limited the use to it.After changing its agent into tablet, the curative effect that both can keep former dosage form, tablet adopts film coating simultaneously, increased stability of drug, and volume reduces, taking convenience, and again because it is a solid preparation, transportation, easy to carry, steady quality, overcome the shortcoming of former preparation, met the modern requirement of Chinese medicine preparation.The present invention has carried out a large amount of tests to its supplementary product kind and consumption, the adjuvant of screening and principal agent reasonable mixture ratio, and technology is rationally feasible through lab scale, pilot scale, and is stable and controllable for quality, and suitable the amplification produces, and drug effect improves a lot, and meets the modern requirement of Chinese medicine preparation.
The inventor has carried out a series of experiments, and is rationally feasible, quality controllable with proof technology of the present invention, to guarantee the beneficial effect of medicine.
Experimental example 1: Study on extraction
Get Spica Prunellae 80g, Radix Stephaniae Tetrandrae 53.2g, Herba Lycopi 24g, Herba Siegesbeckiae 40g, Fructus Ligustri Lucidi 40g, Semen Coicis 80g, Radix Salviae Miltiorrhizae 40g, Folium Mahoniae 40g, Rhizoma Smilacis Glabrae 53.2g, Radix Angelicae Sinensis 26.8g, Radix Astragali 53.2g Retinervus Luffae Fructus 40g, Radix Cyathulae 26.8g for a, nominal is got three parts, adding 6 times, 8 times, 10 times water gagings respectively decocts 2 times, each 2 hours, merge decocting liquid, concentrate, drying gets three parts of dry extracts.Total amount with protocatechualdehyde in the extract is a selection indicators, and amount of water has carried out preferred research, the results are shown in Table 1.
Table 1 amount of water preference data table
| Sample number | Inventory (g) | Add the water multiple | Protocatechualdehyde total amount (mg) |
| 1 2 3 | 597.2 597.2 597.2 | 10 8 6 | 29.25 29.13 23.19 |
Above result shows that solvent load has certain influence to extraction effect, and 8 times of extractions with 10 times of amount of water are complete than 6 times of amounts, and the extraction effect of 8 times of amounts and 10 times of amounts is suitable, so take all factors into consideration from practical factors such as energy consumptions, preferably adding water volume is 8 times of amounts of medical material.
The research of experimental example 2 moulding processs
1, the examination of filler kind:
Tablet filler commonly used is starch, dextrin, lactose, calcium hydrogen phosphate, pregelatinized Starch, microcrystalline Cellulose etc., is filler with one or more of above-mentioned adjuvant, is wetting agent with 95% ethanol, carries out pressure testing; The result is as follows.
The screening of table filler kind
| Prescription | Principal agent (%) | Dextrin (%) | Lactose (%) | Starch (%) | Calcium hydrogen phosphate (%) | Pregelatinized Starch (%) | Microcrystalline Cellulose (%) | Compressibility |
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 | 80 80 80 80 80 80 80 80 80 80 80 80 80 80 80 80 | 20 - - - - - 10 10 - - - 10 6 5 10 - | - 20 - - - - 10 - - 10 - - 6 - 5 5 | - - 20 - - - - - 10 - - - - - - 5 | - - - 20 - - - - - - 10 - - 5 - - | - - - - 20 - - - 10 - 10 10 - - - - | - - - - - 20 - 10 - 10 - - 8 10 5 10 | General better general better, better more better |
According to The above results, with dextrin, calcium hydrogen phosphate, starch is that then compressibility is general for filler, and be filler with lactose, pregelatinized Starch, microcrystalline Cellulose, compressibility is better, and higher because of the lactose price, institute's tabletting disintegration time is longer, use pregelatinized Starch or microcrystalline Cellulose separately, compressibility is better, and disintegrate is fast than lactose, but still about 40 minutes; And other above-mentioned adjuvants find that prepared granule uses above-mentioned adjuvant fashion more separately when being used, and wherein are used with pregelatinized Starch, microcrystalline Cellulose especially, and the gained grain forming is good, and the every index of the tablet that makes all meets the requirements.So intending adopting pregelatinized Starch, microcrystalline Cellulose is that filler carries out formula optimization, result of study is as follows.
Filler loading is preferred
| Principal agent (g) | Pregelatinized Starch (g) | Microcrystalline Cellulose (g) | The result |
| 80 80 80 | 10 6.67 13.33 | 10 13.33 6.67 | Compressibility is good, disintegration time compressibility about 30 minutes is good, disintegration time compressibility about 20 minutes is good, and disintegration time is about 40 minutes |
According to above result as can be known, select the ratio of microcrystalline Cellulose and pregelatinized Starch to be about at 2: 1 o'clock, the compressibility of tablet is better, and disintegration time is moderate, and the hardness that makes tablet also can reach the requirement of coating.So determine the optimum condition of preparations shaping be: adopt microcrystalline Cellulose and pregelatinized Starch as filler, ratio is 2: 1, and concrete consumption then according to each paste volume that extracts, adds to full dose, gets final product.
2, selection of lubricants
Lubricant commonly used has magnesium stearate, micropowder silica gel, Pulvis Talci, according to trial test, above-mentioned any adjuvant or any and all the other one or more can both satisfy the preparation requirement when being used, but especially with magnesium stearate for well, so preferred magnesium stearate is a lubricant; Consumption examination shows, finds that the consumption of magnesium stearate can both satisfy the preparation requirement 1.5% with interior, especially with 1.0% for well.
Concrete embodiment
Embodiment 1: by the shared umber of each raw material in the synovitis sheet, get following recipe quantity raw material:
Spica Prunellae 800g Radix Stephaniae Tetrandrae 532g Herba Lycopi 240g Herba Siegesbeckiae 400g Fructus Ligustri Lucidi 400g
Semen Coicis 800g Radix Salviae Miltiorrhizae 400g Folium Mahoniae 400g Rhizoma Smilacis Glabrae 532g Radix Angelicae Sinensis 268g
Radix Astragali 532g Retinervus Luffae Fructus 400g Radix Cyathulae 268g
More than 13 the flavor medical materials, decoct with water secondary, add 8 times of water gagings at every turn, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds the ethanol of equivalent, stirs evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), dry, be ground into fine powder, add microcrystalline Cellulose and pregelatinized Starch (2: 1) in right amount, mixing, granulate, drying adds magnesium stearate 5g, is pressed into 1000, the bag film-coat, promptly.
Embodiment 2: by the shared umber of each raw material in the synovitis sheet, get following recipe quantity raw material:
Spica Prunellae 800g Radix Stephaniae Tetrandrae 532g Herba Lycopi 240g Herba Siegesbeckiae 400g Fructus Ligustri Lucidi 400g
Semen Coicis 800g Radix Salviae Miltiorrhizae 400g Folium Mahoniae 400g Rhizoma Smilacis Glabrae 532g Radix Angelicae Sinensis 268g
Radix Astragali 532g Retinervus Luffae Fructus 400g Radix Cyathulae 268g
More than 13 the flavor medical materials, decoct with water secondary, add 10,8 times of water gagings respectively, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds 0.5 times ethanol, stirs evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), dry, be ground into fine powder, heavily about 450g adds calcium hydrogen phosphate and lactose (1: 1) 50g, mixing, granulate, drying adds micropowder silica gel 2.5g, be pressed into 1000, promptly.
Embodiment 3: by the shared umber of each raw material in the synovitis sheet, get following recipe quantity raw material:
Spica Prunellae 800g Radix Stephaniae Tetrandrae 532g Herba Lycopi 240g Herba Siegesbeckiae 400g Fructus Ligustri Lucidi 400g
Semen Coicis 800g Radix Salviae Miltiorrhizae 400g Folium Mahoniae 400g Rhizoma Smilacis Glabrae 532g Radix Angelicae Sinensis 268g
Radix Astragali 532g Retinervus Luffae Fructus 400g Radix Cyathulae 268g
More than 13 the flavor medical materials, decoct with water secondary, add 6 times of water gagings at every turn, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds the ethanol of 2 times of amounts, stirs evenly, left standstill 24 hours, and filtered filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), drying is ground into fine powder, heavily about 350g, add starch 70g, microcrystalline Cellulose 40g, lactose 40g, mixing is granulated drying, add Pulvis Talci 2.5g, be pressed into 1000, the bag film-coat, promptly.
Embodiment 4: by the shared umber of each raw material in the synovitis sheet, get following recipe quantity raw material:
Spica Prunellae 800g Radix Stephaniae Tetrandrae 532g Herba Lycopi 240g Herba Siegesbeckiae 400g Fructus Ligustri Lucidi 400g
Semen Coicis 800g Radix Salviae Miltiorrhizae 400g Folium Mahoniae 400g Rhizoma Smilacis Glabrae 532g Radix Angelicae Sinensis 268g
Radix Astragali 532g Retinervus Luffae Fructus 400g Radix Cyathulae 268g
More than 13 the flavor medical materials, decoct with water secondary, add 8,6 times of water gagings respectively, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), add the ethanol of 1.5 times of amounts, stir evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), drying, be ground into fine powder, add dextrin, calcium carbonate, pregelatinized Starch (1: 2: 2) in right amount, mixing is granulated, dry, be pressed into 1000, coating, promptly.
Embodiment 5: by the shared umber of each raw material in the synovitis sheet, get following recipe quantity raw material:
Spica Prunellae 800g Radix Stephaniae Tetrandrae 532g Herba Lycopi 240g Herba Siegesbeckiae 400g Fructus Ligustri Lucidi 400g
Semen Coicis 800g Radix Salviae Miltiorrhizae 400g Folium Mahoniae 400g Rhizoma Smilacis Glabrae 532g Radix Angelicae Sinensis 268g
Radix Astragali 532g Retinervus Luffae Fructus 400g Radix Cyathulae 268g
More than 13 the flavor medical materials, decoct with water secondary, add 10 times of water gagings at every turn, decocted 2 hours, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds the ethanol of equivalent, stir evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), drying, be ground into fine powder, mixing is granulated, drying is pressed into 1000, promptly.
Art for coating can adopt method in the foregoing description, but is not limited to this method:
Art for coating is: 12g Opadry-Y-1-7000 is dissolved in 80% alcoholic solution, soaked 10 minutes, stir, ground 20 minutes through colloidal film, cross 200 mesh sieves and filter, remove coarse granule, with the blockage resisting spray gun, it is standby to make film liquid; Going fine powder to place the plain sheet sieve of suppressing is preheated in the coating pan about 45 ℃, start air compressor machine, open air cock, and the flow of regulating both makes carefully and uniformly vaporific, spray velocity do not cause powder to fly upward with control and in time drying be advisable, continue stirring at coating process film liquid; The coating parameter is: spray gun diameter: 1.4mm, nozzle and sheet bed spacing: 150mm, intake: 7m2/min, inlet temperature: 55 ℃, the gate temperature: preheating 5rpm/ changes, and coating: 12rpm/ changes, and drying: 5rpm/ changes, whiff pressure: 0.15mpa, hydrojet speed: 49g/min, drying: be placed on tray, placed the silica dehydrator chamber 3 hours.
Claims (9)
1, a kind of have a clearing away heat-damp and promoting diuresis, and the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral is characterized in that, counts by weight percentage, and it is mainly to be prepared from by active ingredient 90-70% and adjuvant 10-30%.
2, a kind of clearing away heat-damp and promoting diuresis that has according to claim 1, the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral, it is characterized in that described active ingredient mainly is made up of following raw material medicaments in part by weight: 2 parts of Spica Prunellaes, 1.33 parts of Radixs Stephaniae Tetrandrae, Herba Lycopi's 0.6 1 part of Fen, Herba Siegesbeckiae, 1 part of Fructus Ligustri Lucidi, 2 parts of Semen Coiciss, 1 part of Radix Salviae Miltiorrhizae, 1 part of Folium Mahoniae, 1.33 parts of Rhizoma Smilacis Glabraes, 0.67 part of Radix Angelicae Sinensis, 1.33 parts of the Radixs Astragali, 1 part of Retinervus Luffae Fructus, 0.67 part of Radix Cyathulae.
3. a kind of clearing away heat-damp and promoting diuresis that has according to claim 1, the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral is characterized in that, described preparation is meant tablet.
4, according to claim 1,3 described a kind of clearing away heat-damp and promoting diuresis that have, the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral, it is characterized in that adjuvant includes but not limited to one or more of solvable or microsolubility calcium salt, starch, dextrin, lactose, pregelatinized Starch, microcrystalline Cellulose, micropowder silica gel, Pulvis Talci, magnesium stearate.
5, a kind of clearing away heat-damp and promoting diuresis that has according to claim 4, the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral is characterized in that, described adjuvant is meant microcrystalline Cellulose, pregelatinized Starch, magnesium stearate.
6, according to claim 1,2 described a kind of clearing away heat-damp and promoting diuresis that have, the preparation method of the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral, it is characterized in that, get 13 flavor medical materials such as Spica Prunellae, Radix Stephaniae Tetrandrae, decoct with water secondary, each 2 hours, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), add ethanol, stir evenly, leave standstill, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), and drying is ground into fine powder, add adjuvant or do not add adjuvant, be prepared into required preparation with common process.
7, a kind of clearing away heat-damp and promoting diuresis that has according to claim 6, the preparation method of the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral is characterized in that, this tablet is preparation like this: get Spica Prunellae, 13 flavor medical materials such as Radix Stephaniae Tetrandrae decoct with water secondary, add 6-10 times of water gaging at every turn, decocted 2 hours, collecting decoction filters, filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), adds the ethanol that 0.5-3 doubly measures, and stirs evenly, left standstill 24 hours, and filtered filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), drying is ground into fine powder, adds right amount of auxiliary materials, mixing, granulate drying, tabletting, coating or coating not, promptly.
8, a kind of clearing away heat-damp and promoting diuresis that has according to claim 7, the preparation method of the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral is characterized in that, this tablet is preparation like this: get Spica Prunellae, 13 flavor medical materials such as Radix Stephaniae Tetrandrae decoct with water secondary, add 8 times of water gagings at every turn, decocted 2 hours, collecting decoction filters, and filtrate is concentrated into the clear paste that relative density is 1.05～1.14 (66 ℃), the ethanol that adds equivalent, stir evenly, left standstill 24 hours, filter, filtrate recycling ethanol, being concentrated into relative density is the thick paste of 1.34～1.36 (66 ℃), and drying is ground into fine powder, it is an amount of to add microcrystalline Cellulose and pregelatinized Starch (2: 1), mixing is granulated drying, add 1.0% magnesium stearate, tabletting, the bag film-coat, promptly.
9, a kind of clearing away heat-damp and promoting diuresis that has according to claim 8, the preparation method of the Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral, it is characterized in that the art for coating of tablet is: Opadry-Y-1-7000 is dissolved in 80% alcoholic solution, soaked 10 minutes, stir, ground 20 minutes through colloidal film, cross 200 mesh sieves and filter, remove coarse granule, with the blockage resisting spray gun, it is standby to make film liquid; Going fine powder to place the plain sheet sieve of suppressing is preheated in the coating pan about 45 ℃, start air compressor machine, open air cock, and the flow of regulating both makes carefully and uniformly vaporific, spray velocity do not cause powder to fly upward with control and in time drying be advisable, continue stirring at coating process film liquid; The coating parameter is: spray gun diameter: 1.4mm, nozzle and sheet bed spacing: 150mm, intake: 7m
2/ min, inlet temperature: 55 ℃, the gate temperature: preheating 5rpm/ changes, and coating: 12rpm/ changes, and drying: 5rpm/ changes, whiff pressure: 0.15mpa, hydrojet speed: 49g/min, drying: be placed on tray, placed the silica dehydrator chamber 3 hours; Promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100669213A CN100569221C (en) | 2006-04-03 | 2006-04-03 | A kind of have clearing away heat-damp and promoting diuresis, Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100669213A CN100569221C (en) | 2006-04-03 | 2006-04-03 | A kind of have clearing away heat-damp and promoting diuresis, Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101049442A true CN101049442A (en) | 2007-10-10 |
| CN100569221C CN100569221C (en) | 2009-12-16 |
Family
ID=38781178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100669213A Active CN100569221C (en) | 2006-04-03 | 2006-04-03 | A kind of have clearing away heat-damp and promoting diuresis, Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100569221C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940822A (en) * | 2012-12-06 | 2013-02-27 | 神威药业（张家口）有限公司 | Synovitis treating medicine and preparation method thereof |
| CN102940823A (en) * | 2012-12-06 | 2013-02-27 | 神威药业（张家口）有限公司 | Synovitis treating medicine and preparation method thereof |
| CN104958417A (en) * | 2015-07-30 | 2015-10-07 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to damp-heat blocking collaterals |
| CN105521337A (en) * | 2016-01-14 | 2016-04-27 | 田均庆 | Ointment for treating synovitis in department of orthopedics and traumatology and preparation method of ointment |
| CN106214878A (en) * | 2016-08-31 | 2016-12-14 | 山东省文登整骨医院 | A kind of Chinese medicine composition treating synovitis |
-
2006
- 2006-04-03 CN CNB2006100669213A patent/CN100569221C/en active Active
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102940822A (en) * | 2012-12-06 | 2013-02-27 | 神威药业（张家口）有限公司 | Synovitis treating medicine and preparation method thereof |
| CN102940823A (en) * | 2012-12-06 | 2013-02-27 | 神威药业（张家口）有限公司 | Synovitis treating medicine and preparation method thereof |
| CN102940822B (en) * | 2012-12-06 | 2014-07-16 | 神威药业（张家口）有限公司 | Synovitis treating medicine and preparation method thereof |
| CN104958417A (en) * | 2015-07-30 | 2015-10-07 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to damp-heat blocking collaterals |
| CN105521337A (en) * | 2016-01-14 | 2016-04-27 | 田均庆 | Ointment for treating synovitis in department of orthopedics and traumatology and preparation method of ointment |
| CN106214878A (en) * | 2016-08-31 | 2016-12-14 | 山东省文登整骨医院 | A kind of Chinese medicine composition treating synovitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100569221C (en) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101085223A (en) | Medicine for treating rheumatism and rheumatoid disease | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN1876053A (en) | A pharmaceutical used for moxibustion and preparation method thereof | |
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN100569221C (en) | A kind of have clearing away heat-damp and promoting diuresis, Chinese medicine preparation of promoting blood circulation to remove obstruction in the collateral and preparation method thereof | |
| CN1712054A (en) | Qinchuan Tongbi tablet | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN104922363A (en) | Traditional Chinese medicine composite for treating osteoproliferation | |
| CN1478525A (en) | Medicated wine for treating traumatic injury | |
| CN103690673A (en) | Formula capsules for treating rheumatism | |
| CN1310014A (en) | Lumbago treating Chinese medicine | |
| CN1298376C (en) | Pure Chinese medicine capsule for treating psora and its preparation technology | |
| CN1186067C (en) | Medicine for curing acute injury of muscle and tendon and its preparation method | |
| CN1631430A (en) | Chinese medicinal ointment for treating bone diseases | |
| CN100398143C (en) | Medicament for treating vitiligo | |
| CN101433651A (en) | Plaster for treating painful swelling | |
| CN1160102C (en) | Chinese medicine for curing female chronic inflammation | |
| CN104288597A (en) | Traditional Chinese medicine composition for treating herpes zoster | |
| CN100355441C (en) | Medicine for treating rheumatic and rheumatoid diseases | |
| CN1814145A (en) | Chinese medicine composition for treating colpitis and use thereof | |
| CN1305508C (en) | Pill for treating coronary heart disease | |
| CN1064532C (en) | Pill for pelvic inflammation and cervical erosion | |
| CN101028445A (en) | Chinese medicine for treating ichthyosis | |
| CN1248706C (en) | Pillworm application for preparing medicine for treating osteoproliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Effective date: 20110830 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110830 Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee after: Beijing Increase Pharmaceutical Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: Beijing Yinkeruisi Biological Products Research Institute |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHUHAI BAODE RUNSHENG HEALTH TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY CO., LTD. Effective date: 20150320 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100088 XICHENG, BEIJING TO: 519040 ZHUHAI, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150320 Address after: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee after: Zhuhai Bao Derun Health Technology Co., Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 4002 Patentee before: Beijing Increase Pharmaceutical Technology Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161223 Address after: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. Address before: 519040 Guangdong city of Zhuhai province Jinwan District Sanzao Town Airport Road No. 288 building four floor F area B Patentee before: Zhuhai Bao Derun Health Technology Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170630 Address after: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee after: Beijing Kerui innovative drug research Co. Ltd. Address before: Beijing city Changping District town Beiqijia Hongfu building room 1009 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE CO., LTD. |